

## Morning Update

22nd June 2020

### Snapshot

- Dr Reddy's Laboratories Limited announced the launch of Abiraterone Acetate Tablets in the US market, following approval from the US Food and Drug Administration (USFDA).
- The Reserve Bank of India (RBI) has said no to Yes Bank's request for payment of interest due as on June 29 for Upper Tier II bonds on account of inadequate capital levels, the bank said in an exchange filing on June 20.
- HDFC to raise Rs 14,000 crore through issuance of equity shares or Compulsory Convertible Debentures, non-convertible debentures along with warrants, foreign currency convertible bonds or any other security through QIP or any other permissible mode. Funds are being raised to augment the long-term resources of the company to finance organic or inorganic business opportunities that may arise in financial services including housing finance where the subsidiaries operate, to maintain sufficient liquidity and for general corporate purposes.
- HDFC Bank Board of Directors approve the issue of Perpetual Debt Instruments (part of additional tier-I capital), tier-II capital bonds and long-term bonds up to a total of Rs 50,000 crore over the next 12 months on a private placement basis subject to shareholder approval at the AGM.
- Cipla launches Cipremi (Remdesivir Lyophilised powder for injection 100 mg), the only U.S. FDA approved Emergency Use Authorisation treatment for patients with severe Covid-19 symptoms. Gilead Sciences has extended a voluntary non-exclusive license to Cipla. The company has received approval from the Drug Controller General of India to manufacture and market the generic version of remdesivir.
- Bank of Baroda has announced the closure of its overseas subsidiary at Ghana and has surrendered its banking license to the country's banking regulator.
- **Oil India** the Pollution Control Board, Assam (PCBA) has served a closure notice to state owned Oil India Ltd (OIL) to shut down all production along with drilling operations at its Baghjan oilfield in Tinsukia district of Assam.
- Glenmark gets manufacturing and marketing approval from India's drug regulator to launch the oral antiviral drug Favipiravir to treat mild to moderate Covid-19 patients in India.
- Ashok Leyland approves issue of listed, secured, redeemable NCDs worth Rs 200 crore on a private placement basis in one or more tranches.
- Deepak Nitrite ICRA re-affirms the long-term rating of the Line of Credit at AA- and short-term rating at A1+ assigned to the fund-based limits and non-fund based limits of the company. Outlook on the long-term rating has been revised to stable from positive. Re-affirms the rating at A1+ assigned to its commercial paper program.
- Minda Industries: Issues commercial paper worth Rs 50 crore and is due for maturity on September 17, 2020. The step is in-line with the management's efforts to bring down finance costs.

### Pivot Points

| Category   | L1       | L2       | L3       |
|------------|----------|----------|----------|
| Nifty      | 9920.90  | 9996.80  | 10120.60 |
| Bank Nifty | 18113.63 | 18810.37 | 20074.23 |

### FII & DII Data (₹ Crore)

| Category | Buy Val | Sell Val | Net Val |
|----------|---------|----------|---------|
| FII      | 14764   | 13527    | 1237    |
| DII      | 6511    | 7392     | -880    |

### Index Screenshot

| Index          | Close     | Pts Chg | % Chg  |
|----------------|-----------|---------|--------|
| BSE Sensex     | 34,731.73 | +523.68 | +1.53% |
| Nifty 50       | 10,244.40 | +152.75 | +1.51% |
| Nifty Fut      | 10,212.00 | -34.70  | -0.34% |
| Nifty Bank     | 21,338.10 | +381.80 | +1.82% |
| Nifty Bank Fut | 21,310.00 | +414.15 | +1.98% |
| Dow Jones      | 25,871.46 | -208.64 | -0.80% |
| Nasdaq 100     | 10,008.64 | -3.41   | -0.03% |
| S&P 500        | 3,098.02  | -17.32  | -0.56% |

### Advance & Decline

| Category | Adv  | Dec | Unchg |
|----------|------|-----|-------|
| NSE      | 1277 | 582 | 53    |
| BSE      | 1775 | 880 | 144   |

### Currency

| Commodity | LTP     | Pts Chg | %Chg   |
|-----------|---------|---------|--------|
| USD/INR   | 76.240  | -0.010  | -0.01% |
| EUR/INR   | 85.3315 | +0.0445 | +0.05% |
| EUR/USD   | 1.1192  | +0.0017 | +0.15% |
| GBP/USD   | 1.2370  | +0.0014 | +0.11% |

### Commodity

| Commodity     | LTP      | Pts Chg | %Chg   |
|---------------|----------|---------|--------|
| Gold          | 1,769.05 | +16.05  | +0.92% |
| Silver        | 18.090   | +0.243  | +1.36% |
| Brent Crude   | 42.16    | -0.03   | -0.07% |
| WTI Crude Oil | 39.77    | -0.06   | -0.15% |

## Coronavirus Pandemic Update

| <b>5Country</b> | <b>Total Cases</b> | <b>New Cases</b> | <b>Total Deaths</b> | <b>New Deaths</b> | <b>Total Recovered</b> | <b>Active Cases</b> |
|-----------------|--------------------|------------------|---------------------|-------------------|------------------------|---------------------|
| <b>India</b>    | 426,910            |                  | 13,703              |                   | 237,252                | 175,955             |
| <b>China</b>    | 83,396             | +18              | 4,634               |                   | 78,413                 | 349                 |
| <b>Italy</b>    | 238,499            |                  | 34,634              |                   | 182,893                | 20,972              |
| <b>USA</b>      | 2,356,657          |                  | 122,247             |                   | 980,355                | 1,254,055           |

## Bulk Deals

| <b>Date</b> | <b>Security code</b> | <b>Security Name</b> | <b>Client name</b>   | <b>Buy/Sell</b> | <b>Qty Traded</b> | <b>Traded Price</b> |
|-------------|----------------------|----------------------|----------------------|-----------------|-------------------|---------------------|
|             |                      | BHEL                 | HRTI PRIVATE LIMITED | B               | 215,27,212        | 30.79               |
|             |                      | BHEL                 | HRTI PRIVATE LIMITED | S               | 215,27,212        | 30.85               |

## DISCLAIMER

### Prepared By:

Research Associate (Denil Shah, MMS)  
Email ID: [denilshah@adroitfinancial.com](mailto:denilshah@adroitfinancial.com)  
Phone Number: 0120-4550300\*270/388

Research Analyst (Piyush Yadav, MBA)  
Email ID: [piyushyadav@adroitfinancial.com](mailto:piyushyadav@adroitfinancial.com)  
Phone Number: 0120-4550300\*270/388

Adroit Financial Services Private Limited (hereinafter referred to as "Adroit") is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and Metropolitan Stock Exchange Limited. It is also registered as a Depository Participant with CDSL and NSDL. **Adroit Financial Services Private Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide Registration Number INH100003084.** Adroit or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities Market. Adroit or its associates/analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months.

This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Neither Adroit, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Adroit Financial Services Private Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document.